SCHEMBL19384145

SCHEMBL19384145

CN(CCOc1ccccc1C1(C(N)=O)CC1)C(=O)OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.38
TP53 P04637 1/20 0.37
HRH1 P35367 1/20 0.37
F13A1 P00488 1/20 0.37
TGM2 P21980 1/20 0.37
TGM1 P22735 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
RBP4 P02753 1/20 0.35
DRD2 P14416 1/20 0.35
DRD1 P21728 1/20 0.35
DRD4 P21917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524534 0.87 HDAC1 (0.39) HDAC1TP53HRH1F13A1TGM2
SCHEMBL10102483 0.86 ALDH1A1 (0.40) HDAC1TP53HRH1F13A1TGM2
SCHEMBL19384148 0.85 KDM4E (0.43) HRH1ALDH1A1KDM4ESMN1; SMN2RBP4
SCHEMBL19384146 0.82 HTR1D (0.51) ALDH1A1KDM4ESMN1; SMN2L3MBTL1
SCHEMBL19384156 0.82 CTSL (0.38) HDAC1TP53HRH1F13A1TGM2
Trifluoroacetic Acid SCHEMBL523116 0.82 RBP4 (0.39) HDAC1TP53HRH1ALDH1A1KDM4E
SCHEMBL20854266 0.77 F13A1 (0.39) TP53F13A1TGM2TGM1PDE4A
SCHEMBL450708 0.76 HTT (0.47) ALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL29777971 0.75 ALDH1A1 (0.43) HRH1ALDH1A1KDM4ERBP4HTT
SCHEMBL19384151 0.75 HRH1 (0.46) HRH1F13A1TGM2TGM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190100498-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2019-04-04 US disclosed
US-20190100498-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2019-04-04 US disclosed
EP-3433237-A1 CRYSTALLINE FORM Astrazeneca AB (SE) 2019-01-30 EP disclosed
WO-2017162304-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2017-09-28 WO disclosed
WO-2017162304-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2017-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190100498-A1 CRYSTALLINE FORM GYS2, PYGL, SFPQ HDAC1 1506/4885TP53 637/4885HRH1 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.